President Joe Biden has crossed the line from ill-advised policy to government theft of intellectual property in the White House’s latest economically disastrous move. The Biden-Harris administration’s announcement of its proposed framework on the use of “march-in rights” to seize patents from certain taxpayer-funded drugs is a clear regulatory overreach, distorting the 1980 Bayh-Dole Act. The administration’s manipulation of this law, designed to incentivize private-public collaboration, will have the opposite effect, serving as the ultimate deterrent for research and investment in critical new cures. This use of the Bayh-Dole Act also sets a dangerous precedent for federal intervention across a variety of industries.